Preliminary real-world data from IMCAS 2026 confirm what practitioners already experience: babyGLOW™ with the 8-point technique delivers consistent, natural and immediate results – with high patient satisfaction and minimal risk.
The 8-point technique is an advanced, structured injection technique developed specifically for use with TEOSYAL Redensity 1 as part of the babyGLOW™ protocol from Teoxane. The technique is based on carefully defined anatomical landmarks and safe injection points in order to ensure consistent and predictable results.
TEOSYAL Redensity 1 is a non-cross-linked hyaluronic acid enriched with Teoxane's patented Dermo-Restructuring Complex – amino acids, antioxidants, minerals and vitamins that support the skin's extracellular environment. The product is distributed evenly in the skin via the eight defined injection points for optimal effect.
Preliminary real-world data presented by Teoxane at the IMCAS 2026 conference document the efficacy and safety of the babyGLOW™ protocol. The study included nearly 80 female patients from several European countries – divided into two groups: skin beautification (aged 20–35) and skin rejuvenation (aged 36–55).
Source: Teoxane, presented at IMCAS 2026. These are the manufacturer's own preliminary real-world data — not an independent peer-reviewed clinical study.
HCP evaluation · Nearly 80 patients · Several European countries
| Satisfaction with result | 98% |
| Immediate improvement | 97% |
| Improved radiance | 72,3% |
| Increased skin firmness | 61,2% |
| Significant adverse events | None |
| Immediate radiance | 98% |
| Natural results | 98% |
| Increased self-confidence | 84% |
| No downtime | 98% |
| Satisfied after the course | 93% |
By offering babyGLOW™ with the 8-point technique, the clinic positions itself with documented treatments, natural results and high patient satisfaction – without a focus on volume and with minimal risk. BC Nordic offers products, training and professional support for implementation.
See the product – TEOSYAL Redensity 1 →
Contact us for information about the babyGLOW™ protocol, TEOSYAL Redensity 1 and the entire Teoxane portfolio – we will help you get started with products, training and professional support.
Contact us →The IMCAS 2026 data are preliminary real-world results presented by Teoxane, and not final published independent clinical documentation.
